Bioxytran, Inc (BIXT) stock
BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Bioxytran shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Bioxytran's shares outstanding was 114M at Jun 30, 2026. For fiscal 2025 it was 92M, down 33.7% from the year before. Over ten years it grew 24.7% a year on average. The highest annual figure on record is 139M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92M | -33.7% |
| FY2024 | Dec 31, 2024 | 139M | +3.5% |
| FY2023 | Dec 31, 2023 | 134M | +18.9% |
| FY2022 | Dec 31, 2022 | 113M | +6.1% |
| FY2021 | Dec 31, 2021 | 106M | +13.1% |
| FY2020 | Dec 31, 2020 | 94M | +9.8% |
| FY2019 | Dec 31, 2019 | 86M | +0.6% |
| FY2018 | Dec 31, 2018 | 85M | +115.5% |
| FY2017 | Dec 31, 2017 | 39M | +49.0% |
| FY2016 | Dec 31, 2016 | 27M | +162.9% |
| FY2015 | Dec 31, 2015 | 10M | +126.4% |
| FY2014 | Dec 31, 2014 | 4M | +18.7% |
| FY2013 | Dec 31, 2013 | 4M | +42.2% |
| FY2012 | Dec 31, 2012 | 3M | +87.4% |
| FY2011 | Dec 31, 2011 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 114M | +28.7% |
| Q1 FY2026 | Mar 31, 2026 | 112M | +26.4% |
| Q4 FY2025 | Dec 31, 2025 | 101M | +8.2% |
| Q3 FY2025 | Sep 30, 2025 | 89M | -29.6% |
| Q2 FY2025 | Jun 30, 2025 | 89M | -49.7% |
| Q1 FY2025 | Mar 31, 2025 | 89M | -45.6% |
| Q4 FY2024 | Dec 31, 2024 | 93M | -37.0% |
| Q3 FY2024 | Sep 30, 2024 | 126M | -7.4% |
| Q2 FY2024 | Jun 30, 2024 | 177M | +37.1% |
| Q1 FY2024 | Mar 31, 2024 | 163M | +32.4% |
| Q4 FY2023 | Dec 31, 2023 | 148M | +30.9% |
| Q3 FY2023 | Sep 30, 2023 | 136M | +17.2% |
| Q2 FY2023 | Jun 30, 2023 | 129M | +16.2% |
| Q1 FY2023 | Mar 31, 2023 | 123M | +11.4% |
| Q4 FY2022 | Dec 31, 2022 | 113M | +2.4% |
| Q3 FY2022 | Sep 30, 2022 | 116M | +5.9% |
| Q2 FY2022 | Jun 30, 2022 | 111M | +7.2% |
| Q1 FY2022 | Mar 31, 2022 | 111M | +10.7% |
| Q4 FY2021 | Dec 31, 2021 | 110M | +10.7% |
| Q3 FY2021 | Sep 30, 2021 | 110M | +13.1% |
| Q2 FY2021 | Jun 30, 2021 | 103M | +6.5% |
| Q1 FY2021 | Mar 31, 2021 | 100M | +14.7% |
| Q4 FY2020 | Dec 31, 2020 | 99M | +14.2% |
| Q3 FY2020 | Sep 30, 2020 | 97M | +14.0% |
| Q2 FY2020 | Jun 30, 2020 | 97M | +14.0% |
| Q1 FY2020 | Mar 31, 2020 | 87M | +2.5% |
| Q4 FY2019 | Dec 31, 2019 | 87M | +2.2% |
| Q3 FY2019 | Sep 30, 2019 | 85M | +0.1% |
| Q2 FY2019 | Jun 30, 2019 | 85M | +0.0% |
| Q1 FY2019 | Mar 31, 2019 | 85M | 0.0% |
| Q4 FY2018 | Dec 31, 2018 | 85M | +9.7% |
| Q3 FY2018 | Sep 30, 2018 | 85M | +167.1% |
| Q2 FY2018 | Jun 30, 2018 | 85M | +167.1% |
| Q1 FY2018 | Mar 31, 2018 | 85M | +248.2% |
| Q4 FY2017 | Dec 31, 2017 | 78M | +158.7% |
| Q3 FY2017 | Sep 30, 2017 | 32M | +21.6% |
| Q2 FY2017 | Jun 30, 2017 | 32M | – |
| Q1 FY2017 | Mar 31, 2017 | 24M | – |
| Q4 FY2016 | Dec 31, 2016 | 30M | – |
| Q3 FY2016 | Sep 30, 2016 | 26M | – |
See a number that looks wrong?